e-Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2020

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer (#205)

Elgene Lim 1 , Heloisa H Milioli 1 , Sarah Alexandrou 1 , Rhiannon Coulson 2 , Aliza Yong 1 , Kristine J Fernandez 1 , KeeMing Chia 1 , Ensar Halilovic 3 , Davendra Segara 1 , Andrew Parker 1 , Sue Haupt 2 , Ygal Haupt 2 , Wayne D Tilley 4 , Alex Swarbrick 1 , Elizabeth C Caldon 1 , Neil Portman 1
  1. Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia
  2. Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
  3. Novartis Institutes of Biomedical Research, Cambridge, Boston, USA
  4. Dame Roma Mitchell Laboratory, University of Adelaide, Adelaide, South Australia, Australia

Background: Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed via upregulation of its key regulator MDM2. This underlies our rationale to evaluate MDM2 inhibition as a therapeutic strategy in treatment-resistant ER-positive breast cancer.

Methods: We used the MDM2 inhibitor NVP-CGM097 to treat in vitro and in vivo models alone and in combination with fulvestrant or palbociclib. We perform cell viability, cell cycle, apoptosis and senescence assays to evaluate antitumour effects in p53 wildtype and p53 mutant ER-positive cell lines (MCF-7, ZR75-1, T-47D) and MCF-7 lines resistant to endocrine therapy and to CDK4/6 inhibition. We further assess the drug effects in patient-derived xenograft (PDX) models of endocrine-sensitive and endocrine-resistant ER-positive breast cancer.

Results: We demonstrate that MDM2 inhibition results in cell cycle arrest and increased apoptosis in p53-wildtype in vitro and in vivo breast cancer models, leading to potent anti-tumour activity. We find that endocrine therapy or CDK4/6 inhibition synergises with MDM2 inhibition but does not further enhance apoptosis. Instead, combination treatments result in profound regulation of cell cycle-related transcriptional programmes, with synergy achieved through increased antagonism of cell cycle progression. Combination therapy pushes cell lines resistant to fulvestrant or palbociclib to become senescent and significantly reduces tumour growth in a fulvestrant-resistant patient-derived xenograft model.

Conclusions: We conclude that MDM2 inhibitors in combination with ER degraders or CDK4/6 inhibitors represent a rational strategy for treating advanced, endocrine-resistant ER-positive breast cancer, operating through synergistic activation of cell cycle co-regulatory programmes.